Physician profile
Bernard Topi
NPI 1811175391
$6,673.30
in general payments reported to CMS, 2019-2025
39 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $480 · 2021: $594 · 2022: $810 · 2023: $1,028 · 2024: $1,239 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,078.16 | 2021-2025 | Cobalt Dr Mri Surescan, Linq II, Turbohawk |
| Pfizer INC. | $580.81 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $557.05 | 2019-2024 | Xarelto |
| Abbott Laboratories | $503.62 | 2019-2022 | |
| Amgen INC. | $452.89 | 2019-2025 | Repatha, Repatha |
| Inari Medical, INC. | $380.17 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $288.46 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $285.63 | 2019-2025 | Brilinta, Farxiga, Bevespi Aerosphere |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $278.22 | 2019-2025 | Lifevest |
| Penumbra, INC. | $270.34 | 2022-2025 | Indigo System, Penumbra System |
| Boston Scientific Corporation | $251.29 | 2022-2025 | Watchman Flx, General - Therapies, Rotapro |
| Novartis Pharmaceuticals Corporation | $235.38 | 2019-2025 | |
| Esperion Therapeutics, INC. | $165.74 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.56 | 2021-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $123.79 | 2023-2024 | Inpefa |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Topi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.